-

06:14:18 PM

SUPN Stock News

SUPN - Supernus Pharmaceuticals Inc

03/08/23 4:05 PM

Nasdaq : SUPN

conferences

Supernus to Participate in Two Upcoming Investor Conferences

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Supernus Pharmaceuticals management

RHEA-AI

neutral

03/01/23 4:55 PM

Nasdaq : SUPN

conferences

Supernus to Present at the Cowen 43rd Annual Health Care Conference

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of

RHEA-AI

neutral

02/28/23 4:05 PM

Nasdaq : SUPN

earnings

Supernus Announces Fourth Quarter and Full Year 2022 Financial Results

Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021 Fourth quarter 2022 Qelbree ® net product sales of $23.6 million increased 29% compared to third quarter of 2022; Full year 2022 Qelbree net product sales of $61.3 million, compared to $9.9 million for full

RHEA-AI

neutral

02/14/23 4:30 PM

Nasdaq : SUPN

Supernus Enters Into $150 Million Credit Facility

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it entered into a credit line agreement (the

RHEA-AI

neutral

02/09/23 6:15 PM

Nasdaq : SUPN

earnings

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial

RHEA-AI

neutral

11/22/22 5:00 PM

Nasdaq : SUPN

conferences

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of

RHEA-AI

neutral

11/08/22 5:30 PM

Nasdaq : SUPN

conferences

Supernus to Present at Two November Healthcare Conferences

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of

RHEA-AI

neutral

11/08/22 4:05 PM

Nasdaq : SUPN

earnings

Supernus Announces Third Quarter 2022 Financial Results

Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously Increasing full year 2022 total revenues guidance to $650 million to

RHEA-AI

neutral

10/25/22 4:30 PM

Nasdaq : SUPN

earnings

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial

RHEA-AI

neutral

10/10/22 8:30 AM

Nasdaq : SUPN

Supernus Provides Regulatory Update on SPN-830

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA)

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

SUPN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.supernus.com
CeoJack Khattar
Security nameSupernus Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees575
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address9715 Key West Avenue
StateMaryland
CityRockville
Zip20850
CountryUS
Phone13018382500

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.